
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is positioned for continued financial improvement, with expectations for gross and net margins to enhance due to a favorable product mix and robust balance sheet, potentially leading to a debt-free status by next year. The Human Nutrition and Health segment is anticipated to drive accelerated revenue growth, which will contribute to sequential revenue gains in upcoming quarters. Additionally, projections for GAAP earnings indicate a positive trajectory, with estimates rising to $4.01 per share for 2024 and $4.47 for 2025, underscoring the company's strength in high-margin markets.
Bears say
The financial analysis indicates a concerning outlook for Balchem Corp due to a projected decline in earnings, with expected GAAP earnings for full-year 2025 revised down to $4.22 per diluted share from a prior estimate of $4.47. Additionally, there are significant risks associated with the company’s growth trajectory, including potential slowdowns in its base businesses, inflationary pressures, and challenges in launching new products, all of which could impact revenue generation. Furthermore, the company faces external threats related to regional conflicts that may disrupt its European operations, compounding the negatives surrounding its financial performance.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares